Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
CTOS 2020 – Karyopharm seeks a solid tumour Seal of approval
Despite the lack of an overall survival benefit the Seal study gives Karyopharm enough to file for Xpovio’s first solid tumour use.
Go or no go? A busy month ahead for US FDA decisions
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Karyopharm comes to Boston for the springtime
Karyopharm’s newly approved myeloma drug, Xpovio, has shown promise in earlier lines of therapy, but toxicity could still cap its potential.
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev nous
Karyopharm hopes to move Xpovio earlier in the multiple myeloma treatment sequence, and data are due for Akcea/Ionis’s triglyceride regulator, for which Pfizer paid a…
